Carboxamide compounds and their use as calpain inhibitors

    公开(公告)号:US09150553B2

    公开(公告)日:2015-10-06

    申请号:US12810795

    申请日:2008-12-29

    CPC分类号: C07D405/14 C07D491/052

    摘要: The present invention relates to novel carboxamide compounds of the formula I and their use for the manufacture of a medicament. The carboxamide compounds are prodrugs of inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. R1 is C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C4-alkyl, aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl, hetaryl-C1-C4-alkyl or hetaryl-C2-C6-alkenyl, R2 is C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C4-alkyl, aryl, O-aryl, O—CH2-aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl, hetaryl-C1-C4-alkyl or hetaryl-C2-C6-alkenyl, R3a and R3b together form a moiety S-Alk-S, O-Alk-S or O-Alk-O, wherein Alk is linear C2-C5-alkandiyl, which may be unsubstituted or substituted with 1, 2, 3 or 4 radicals selected from C1-C4-alkyl or halogen; X is a radical of the formulae C(═O)—O—Rx1, C(═O)—NRx2Rx3, C(═O)—N(Rx4)—(C1-C6-alkylene)-NRx2Rx3, C(═O)—N(Rx4)NRx2Rx3, n is 0, 1 or 2, one of the variables Y1, Y2, Y3 or Y4 is a nitrogen atom, and the remaining variables Y1, Y2, Y3 or Y4 are CH; Ry is e.g. OH, SH, halogen, NO2, NH2, CN, CF3, CHF2, CH2F, O—CF3, O—CHF2, O—CH2F, COOH, OCH2COOH, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkoxy-C1-C4-alkyl, C1-C6-alkylthio etc. W is a radical of the formulae W1 or W2 which is linked via nitrogen: in which * means the linkage to the 6-membered heteroaromatic ring, and # means the linkage to R2, m is 0, 1 or 2, and Rw is e.g. OH, SH, halogen, NO2, NH2, CN, CF3, CHF2, CH2F, O—CF3, O—CHF2, O—CH2F, COOH, OCH2COOH.

    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V
    3.
    发明申请
    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V 有权
    羧酰胺化合物及其作为钙抑制剂V

    公开(公告)号:US20140005227A1

    公开(公告)日:2014-01-02

    申请号:US13992582

    申请日:2011-12-08

    IPC分类号: C07D401/04

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R1, R2, R3, R4, X, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted benzyl or hetaryl-methyl, X is a single bond or an oxygen atom, R2 is C1-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or CH2—C(O)OCH3, R3 and R4 independently of one another are halogen, CN, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式(I)的化合物,其中R 1,R 2,R 3,R 4,X,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物和药学上合适的盐 其中。 在这些化合物中,优选其中R 1为任选取代的苄基或杂芳基 - 甲基,X为单键或氧原子,R 2为C 1 -C 4烷基,C 1 -C 4卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 环烷基,C 3 -C 6环烷基-C 1 -C 2烷基,C 3 -C 6杂环烷基-C 1 -C 2烷基,苯基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或CH 2 -C(O)OCH 3,R 3和R 4彼此独立地是卤素,CN,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    Carboxamide compounds and their use as calpain inhibitors IV
    4.
    发明授权
    Carboxamide compounds and their use as calpain inhibitors IV 有权
    羧甲酰胺化合物及其作为钙蛋白酶抑制剂的用途

    公开(公告)号:US08598211B2

    公开(公告)日:2013-12-03

    申请号:US12972679

    申请日:2010-12-20

    IPC分类号: A61K31/4439 C07D401/04

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C3-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or 1,3-benzoxazol-2-yl-methyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 3 -C 4 - 烷基,C 1 -C 4 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基,C 3 -C 6 - 杂环烷基-C 1 -C 2 - 烷基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或1,3-苯并恶唑-2-基 - 甲基,R 4和R 5彼此独立地是卤素 ,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV
    5.
    发明申请
    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV 有权
    羧酰胺化合物及其作为抑制剂的用途IV

    公开(公告)号:US20110152325A1

    公开(公告)日:2011-06-23

    申请号:US12972679

    申请日:2010-12-20

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C3-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or 1,3-benzoxazol-2-yl-methyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 3 -C 4 - 烷基,C 1 -C 4 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基,C 3 -C 6 - 杂环烷基-C 1 -C 2 - 烷基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或1,3-苯并恶唑-2-基 - 甲基,R 4和R 5彼此独立地是卤素 ,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    Carboxamide compounds and their use as calpain inhibitors V
    6.
    发明授权
    Carboxamide compounds and their use as calpain inhibitors V 有权
    羧酰胺化合物及其作为钙蛋白酶抑制剂的用途

    公开(公告)号:US09062027B2

    公开(公告)日:2015-06-23

    申请号:US13992582

    申请日:2011-12-08

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R1, R2, R3, R4, X, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted benzyl or hetaryl-methyl, X is a single bond or an oxygen atom, R2 is C1-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or CH2—C(O)OCH3, R3 and R4 independently of one another are halogen, CN, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式(I)的化合物,其中R 1,R 2,R 3,R 4,X,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物和药学上合适的盐 其中。 在这些化合物中,优选其中R 1为任选取代的苄基或杂芳基 - 甲基,X为单键或氧原子,R 2为C 1 -C 4烷基,C 1 -C 4卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 环烷基,C 3 -C 6环烷基-C 1 -C 2烷基,C 3 -C 6杂环烷基-C 1 -C 2烷基,苯基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或CH 2 -C(O)OCH 3,R 3和R 4彼此独立地是卤素,CN,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    Carboxamide compounds and their use as calpain inhibitors V
    7.
    发明授权
    Carboxamide compounds and their use as calpain inhibitors V 有权
    羧酰胺化合物及其作为钙蛋白酶抑制剂的用途

    公开(公告)号:US09051304B2

    公开(公告)日:2015-06-09

    申请号:US12972663

    申请日:2010-12-20

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C1-C3-alkyl, C1-C3-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, or phenyl-C1-C3-alkyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 1 -C 3 - 烷基,C 1 -C 3 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基或苯基 - C 1 -C 3 - 烷基,R 4和R 5彼此独立地是卤素,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V
    8.
    发明申请
    CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V 有权
    羧酰胺化合物及其作为钙抑制剂V

    公开(公告)号:US20110152265A1

    公开(公告)日:2011-06-23

    申请号:US12972663

    申请日:2010-12-20

    摘要: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C1-C3-alkyl, C1-C3-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, or phenyl-C1-C3-alkyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.

    摘要翻译: 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 1 -C 3 - 烷基,C 1 -C 3 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基或苯基 - C 1 -C 3 - 烷基,R 4和R 5彼此独立地是卤素,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。

    Prodrugs of thrombin inhibitors
    9.
    发明授权
    Prodrugs of thrombin inhibitors 有权
    凝血酶抑制剂的前药

    公开(公告)号:US07144902B1

    公开(公告)日:2006-12-05

    申请号:US09958349

    申请日:2000-04-05

    IPC分类号: A61K31/425 C07D277/20

    摘要: The present invention relates to prodrugs of pharmacologically active five-membered heterocyclic amidines from which are produced in vivo compounds which are competitive inhibitors of trypsin-like serine proteases, in particular thrombin and kininogenases such as kallikrein, to the preparation thereof and to the use thereof as medicines. The invention also relates to pharmaceutical compositions which comprise the prodrugs of the active compounds as ingredients, and to the use of the compounds as thrombin inhibitors, anticoagulants and as antiinflammatory agents.

    摘要翻译: 本发明涉及药理活性五元杂环脒的前体药物,它们是体内化合物,其是胰蛋白酶样丝氨酸蛋白酶的竞争性抑制剂,特别是凝血酶和激肽释放酶如激肽释放酶对其制备及其用途 作为药物 本发明还涉及包含活性化合物作为成分的前药以及该化合物作为凝血酶抑制剂,抗凝剂和抗炎剂的用途的药物组合物。

    Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
    10.
    发明申请
    Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor 失效
    适用于治疗多巴胺D3受体调节反应的三唑化合物

    公开(公告)号:US20080171751A1

    公开(公告)日:2008-07-17

    申请号:US11792596

    申请日:2005-12-01

    CPC分类号: C07D403/12

    摘要: The invention relates to compounds of the formula I: wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R1a is hydrogen or C1-C4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

    摘要翻译: 本发明涉及式I化合物:其中n是1或2,Ar是在剩余的碳原子上带有自由基R 1的C结合的1,2,4-三唑基,和 其中一个氮原子上的基团R 1a, R 1是氢,C 1 -C 6烷基,C 3 -C 6烷基,C 1 -C 6烷基,C 1 -C 6烷基, 氟化C 1 -C 6烷基,氟化C 1 -C 6烷基,C 1 -C 6烷基,C 1 -C 6烷基, 氟化C 1 -C 4烷氧基甲基或任选取代的苯基或5-或6位的C 1 -C 6烷基, 杂芳基; R 1a是氢或C 1 -C 4烷基; R 2是C 1 -C 6烷基,C 3 -C 6烷基,C 3 -C 6烷基,C 3 -C 6烷基,C 3 -C 6烷基, 氟化C 1 -C 6烷基或氟化C 3 -C 6环烷基; 以及这些化合物的生理上耐受的酸加成盐。 本发明还涉及一种药物组合物,其包含至少一种式I的三唑化合物和/或其至少一种生理上耐受的酸加成盐,还涉及治疗有益于多巴胺D 3的病症的方法 受体拮抗剂或多巴胺D 3激动剂,所述方法包括向有需要的受试者施用有效量的至少一种式III的三唑化合物或生理耐受的酸加成盐。